Clover Biopharmaceuticals, Ltd.
HKEX:2197.HK
0.86 (HKD) • At close August 29, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Assets: | ||||||
| Current Assets: | ||||||
| Cash & Cash Equivalents
| 401.243 | 735.864 | 1,607.409 | 2,767.371 | 516.184 | 148.694 |
| Short Term Investments
| 26.284 | 30.393 | 33.172 | 98.796 | 290.328 | 10 |
| Cash and Short Term Investments
| 427.527 | 752.972 | 1,640.581 | 2,866.167 | 806.512 | 158.694 |
| Net Receivables
| 45.638 | 24.106 | 135.147 | 0 | 0 | 0 |
| Inventory
| 11.031 | 696.978 | 2,384.34 | 768.691 | 50.881 | 0.393 |
| Other Current Assets
| 179.013 | 425.463 | 246.161 | 0 | 191.032 | 5.259 |
| Total Current Assets
| 663.209 | 1,899.519 | 4,389.929 | 5,076.495 | 1,048.425 | 164.346 |
| Non-Current Assets: | ||||||
| Property, Plant & Equipment, Net
| 116.181 | 162.056 | 241.744 | 222.403 | 86.987 | 17.428 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 33.354 | 39.859 | 34.998 | 13.828 | 0.277 | 0.294 |
| Goodwill and Intangible Assets
| 33.354 | 39.859 | 34.998 | 13.828 | 0.277 | 0.294 |
| Long Term Investments
| 0 | 0 | 0 | 0 | 0 | 0 |
| Tax Assets
| 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets
| 0 | 0 | 28.035 | 32.934 | 51.839 | 4.148 |
| Total Non-Current Assets
| 149.535 | 201.915 | 304.777 | 269.165 | 139.103 | 21.87 |
| Total Assets
| 812.744 | 2,101.434 | 4,694.706 | 5,345.66 | 1,187.528 | 186.216 |
| Liabilities & Equity: | ||||||
| Current Liabilities: | ||||||
| Account Payables
| 120.453 | 247.829 | 856.964 | 588.559 | 33.82 | 7.165 |
| Short Term Debt
| 86.149 | 326.598 | 317.63 | 21.48 | 4.259 | 1.81 |
| Tax Payables
| 1.097 | 3.067 | 6.284 | 5.919 | 1.422 | 0.083 |
| Deferred Revenue
| 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities
| 1,699.964 | 1,699.509 | 1,648.327 | 1,532.151 | 27.233 | 18.429 |
| Total Current Liabilities
| 1,907.663 | 2,277.003 | 2,829.205 | 2,148.109 | 66.734 | 27.487 |
| Non-Current Liabilities: | ||||||
| Long Term Debt
| 3.495 | 7.853 | 36.738 | 46.44 | 18.057 | 10.645 |
| Deferred Revenue Non-Current
| 0 | 0 | 2,496.9 | 1,931.963 | 958.172 | 17.17 |
| Deferred Tax Liabilities Non-Current
| 0 | 0 | -2,496.9 | -1,931.963 | 0 | 0 |
| Other Non-Current Liabilities
| 537.884 | 549.411 | 0 | 1,931.963 | 1,127.306 | 215.906 |
| Total Non-Current Liabilities
| 541.379 | 557.264 | 2,533.638 | 1,978.403 | 2,103.535 | 226.551 |
| Total Liabilities
| 2,449.042 | 2,834.267 | 5,362.843 | 4,126.512 | 2,170.269 | 254.038 |
| Equity: | ||||||
| Preferred Stock
| 0 | 0 | 0 | 0 | 0 | 0 |
| Common Stock
| 0.838 | 0.838 | 0.835 | 0.742 | 0 | 0 |
| Retained Earnings
| 0 | -9,640.268 | -9,501.729 | -7,049.826 | -1,033.523 | -120.625 |
| Accumulated Other Comprehensive Income/Loss
| 0 | 0 | 270.383 | 296.632 | 50.782 | 52.803 |
| Other Total Stockholders Equity
| -1,637.136 | 8,906.597 | 8,832.757 | 7,971.6 | 0 | 0 |
| Total Shareholders Equity
| -1,636.298 | -732.833 | -668.137 | 1,219.148 | -982.741 | -67.822 |
| Total Equity
| -1,636.298 | -732.833 | -668.137 | 1,219.148 | -982.741 | -67.822 |
| Total Liabilities & Shareholders Equity
| 812.744 | 2,101.434 | 4,694.706 | 5,345.66 | 1,187.528 | 186.216 |